Skip to contentW
Windtree Therapeutics Inc
W
WINTWindtree Therapeutics Inc Q2 2015 · 10-Q
Revenue$75.00K$75.00K−93.1% vs Q2 2014 Net Income-$11.33M-$11.33MN/M vs Q2 2014 EPS Diluted-$1.82-$1.82N/M vs Q2 2014 Operating Income-$10,437,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Windtree Therapeutics Inc · CIK 946486 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,731,000N/M Margins · derivedOperating margin-13916.0%−12914.9 pt vs Q2 2014
Net margin-15101.3%−14129.4 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 10, 2015 · 41 d after period end